Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL82496 | 0.97 | SLC7A5 (0.38) | SLC7A5LMNAALOX15BLMPMP22 | |
| SCHEMBL28611647 | 0.93 | SLC7A5 (0.36) | SLC7A5LMNAALOX15BLMPMP22 | |
| SCHEMBL29128986 | 0.93 | SLC7A5 (0.36) | SLC7A5LMNAALOX15BLMPMP22 | |
| SCHEMBL29053273 | 0.93 | SLC7A5 (0.36) | SLC7A5LMNAALOX15BLMPMP22 | |
| Hydrochloric Acid SCHEMBL6491083 | 0.93 | SLC7A5 (0.36) | SLC7A5LMNAALOX15BLMPMP22 | |
| SCHEMBL29170630 | 0.93 | SLC7A5 (0.36) | SLC7A5LMNAALOX15BLMPMP22 | |
| SCHEMBL29019967 | 0.93 | SLC7A5 (0.36) | SLC7A5LMNAALOX15BLMPMP22 | |
| SCHEMBL27806633 | 0.90 | SLC7A5 (0.38) | SLC7A5LMNAALOX15BLMPMP22 | |
| SCHEMBL14261041 | 0.81 | TP53 (0.33) | SLC7A5LMNAALOX15BLMPMP22 | |
| SCHEMBL21233886 | 0.81 | TP53 (0.33) | SLC7A5LMNAALOX15BLMPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12427157-B2 | Methods for treatment of diseases involving acidic or hypoxic diseased tissues | CYBREXA 1, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-12410262-B2 | Peptide conjugates of cytotoxins as therapeutics | Cybrexa 2, Inc. (US) | 2025-09-09 | — | — | US | disclosed |
| US-12251387-B2 | Substituted quinoxalines and benzo[c][1,2,5]oxadiazoles as DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-03-18 | — | — | US | disclosed |
| US-12234212-B2 | Peptide conjugates of microtubule-targeting agents as therapeutics | Cybrexa 3, Inc. (US) | 2025-02-25 | — | — | US | disclosed |
| EP-3740479-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20240368182-A1 | Substituted Macrocyclic Compounds and Related Methods of Treatment | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2024-11-07 | — | — | US | disclosed |
| US-12121524-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-10-22 | — | — | US | disclosed |
| US-12005127-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-06-11 | — | — | US | disclosed |
| US-12006330-B2 | Substituted macrocyclic compounds and related methods of treatment | ALKERMES, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| CN-111757876-B | DNA-PK inhibitors | 沃泰克斯药物股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-20060079556-A1 | N-sulfonylpiperidine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2006-04-13 | — | — | US | disclosed |
| EP-0471372-B1 | Novel substituted guanidine derivatives, their preparation and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-11-21 | — | — | EP | disclosed |
| US-6020347-A | 4-substituted-4-piperidine carboxamide derivatives | MERCK & CO., INC. (US) | 2000-02-01 | — | — | US | disclosed |
| WO-1999025685-A1 | 4-SUBSTITUTED-4-PIPERIDINE CARBOXAMIDE DERIVATIVES | MERCK & CO., INC. (US) | 1999-05-27 | — | — | WO | disclosed |
| US-5256679-A | Pesticides | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-10-26 | — | — | US | disclosed |
| EP-0471372-A1 | Novel substituted guanidine derivatives, their preparation and use | Takeda Chemical Industries, Ltd. (JP) | 1992-02-19 | — | — | EP | disclosed |
| US-4801710-A | Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives | MERCK & CO., INC. (US) | 1989-01-31 | — | — | US | disclosed |
| EP-0190588-A1 | Quinazolino-1,4-benzodiazepin-6,9-diones, processes for their preparation and pharmaceutical compositions containing them | MERCK & CO. INC. (US) | 1986-08-13 | — | — | EP | disclosed |
| EP-0184473-A1 | Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives | MERCK & CO. INC. (US) | 1986-06-11 | — | — | EP | disclosed |
| US-4554272-A | CHOLECYSTOKININ INHIBITORS | MERCK & CO., INC. (US) | 1985-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410262-B2 | Peptide conjugates of cytotoxins as therapeutics | TOP1, TOP2A, TOP2B | SLC7A5 1635/4885LMNA 2956/4885ALOX15 3660/4885 |
| US-20060079556-A1 | N-sulfonylpiperidine cannabinoid receptor 1 antagonists | CNR1, CNR2, NPY1R | SLC7A5 3746/4885LMNA 4092/4885ALOX15 3054/4885 |
| US-12006330-B2 | Substituted macrocyclic compounds and related methods of treatment | HCRTR2, HCRTR1, CNR2 | SLC7A5 1930/4885LMNA 1390/4885ALOX15 1204/4885 |
| US-12121524-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | SLC7A5 4120/4885LMNA 469/4885ALOX15 4733/4885 |
| US-20240368182-A1 | Substituted Macrocyclic Compounds and Related Methods of Treatment | HCRTR2, HCRTR1, CNR2 | SLC7A5 1930/4885LMNA 1390/4885ALOX15 1204/4885 |
| US-12251387-B2 | Substituted quinoxalines and benzo[c][1,2,5]oxadiazoles as DNA-PK inhibitors | TOP1, TOP2A, TOP2B | SLC7A5 3307/4885LMNA 173/4885ALOX15 3574/4885 |
| US-12005127-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | SLC7A5 4120/4885LMNA 469/4885ALOX15 4733/4885 |
| US-12427157-B2 | Methods for treatment of diseases involving acidic or hypoxic diseased tissues | HIF1A, HIF1AN, EGLN3 | SLC7A5 2418/4885LMNA 672/4885ALOX15 160/4885 |
| US-12234212-B2 | Peptide conjugates of microtubule-targeting agents as therapeutics | MAP4, MAP2, TUBB3 | SLC7A5 1888/4885LMNA 3608/4885ALOX15 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.